NISHITH.TV
  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York

Locations

  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York
  • Content
  • Home
  • ABOUT US
  • NDA in the Media
  • Areas of Service
  • Research and Articles
  • Opportunities
  • Contact
  • NDACloud
  • Client Access
  • Member Access
  • Events and Calender
  • How we perform
  • Knowledge anywhere, anytime
  • See our recent deals
  • Up to date legal developments
  • Case studies in M&A

Research and Articles

HTMLPDF

  • Research at NDA
  • Research Papers
  • Research Articles
  • NDA Think Tanks
  • NDA Hotline
  • New Ali Gunjan
  • Japan Desk ジャパンデスク

NDA-Hotline


  • Debt Funding in India Series
  • Private Equity Corner
  • The Startups Series
  • Court Corner
  • Investment Funds: Monthly Digest
  • Insolvency and Bankruptcy Hotline
  • Deal Destination
  • New Publication
  • M&A Interactive
  • Lit Corner
  • Private Debt Hotline
  • Food & Beverages Hotline
  • Companies Act Series
  • Gaming Law Wrap
  • Private Client Wrap
  • GIFT City Express
  • Regulatory Hotline
  • Capital Markets Hotline
  • Tax Hotline
  • Corpsec Hotline
  • Dispute Resolution Hotline
  • M&A Hotline
  • Pharma & Healthcare Update
  • Competition Law Hotline
  • HR Law Hotline
  • IP Hotline
  • Telecom Hotline
  • FEMA Hotline
  • Social Sector Hotline
  • iCe Hotline
  • SEZ Hotline
  • Media Hotline
  • Funds Hotline
  • Education Sector Hotline
  • International Trade Hotlines
  • Other Hotline
  • Real Estate Update
  • Realty Check
  • White Collar and Investigations Practice
  • Legal Update
  • IP Lab
  • Cross Examination
  • Technology & Tax Series
  • Technology Law Analysis
  • Yes, Governance Matters.
  • Financial Service Update
  • Japan Desk ジャパンデスク

Pharma & Healthcare Update

August 12, 2005

In Pipeline: New Drug policy

By the year end (2005) Indian government is likely to announce a new Drug Policy encompassing Drug Pricing, Funding and Tax policy. The proposed policy is likely to be converted into a statute. This is seen as a significant step in an environment where the Patent Act,1970 has been changed after 35 years by introduction of a product patent regime.

In the year 2002 an attempt was made by the government to bring in Pharmaceutical Policy 2002 - which , inter alia, dealt with price of essential drugs. However, shortly after it was announced it was challenged in the Karnataka High Court and the Supreme Court and till date has not been implemented.

SOME OF THE SALIENT MEASURES RECOMMENDED IN THE NEW POLICY ARE:

PRICE CONTROL:

In the wake of introduction of the product patent regime in India, price control of essential drugs has gained importance.

The government is planning to amend the existing Drug Pricing Control Order, 1995 ("DPCO") in view of the recommendations by the Sandhu Committee and special task force for drug pricing. DPCO is issued under the Essential Commodities Act, 1955.

The Task Force was created by the Prime Minister of India to arrive at a consensus with the Pharma industry to ensure low-cost drugs for the Indian masses without stifling the global dreams of companies and the Sandhu Committee, was constituted to compile a list of drugs that would be brought under price control.

Sandhu committee's suggestions would deal with price control issues, trade margins and bulk purchases. It has recommended that whenever a new drug is patented its price should be negotiated to keep it at a reasonable level. There has been some debate in respect of definition of the term "life saving". The special task force is likely to recommend on debranding of generics as mentioned by the official from chemicals and petrochemicals ministry.

The policy also proposes to strengthen, the National Pharmaceutical Pricing Authority ("NPPA"), the monitoring of executive body of the DPCO. NPPA is an organization of the Government of India, which was established, inter alia, to fix or revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country, under the DPCO. The organization is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers. It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

ESTABLISHMENT OF FUNDS:

The government is contemplating to set up a fund to disburse loans to small companies which likely to be affected by recent implementation of the Good Manufacturing Practices to upgrade and modernize their plants.

GOVERNMENT WEBSITE:

This website would be listing the prices of generic equivalent drugs giving opportunity to consumer to buy the drugs at the cheapest price. This move will increase the public awareness and promote debranding.

ILLNESS ASSISTANCE:

Under this program the below poverty line (BPL) families will be insured for free treatment.

RESEARCH AND DEVELOPMENT:

To boost the Research and Development ("R&D") activities, it proposed to have a tax rebate of 200 per cent for an extended period of 10 years considering the massive R&D expenditure pharma companies would incur in new patent regime era.

- Gowree Gokhale & Milind Antani
 
 

Source: Business Standard August 12, 2005

Mission and Vision


Distinctly Different

What's New


Mid-year Regulatory Update 2022: Pharmaceuticals in India
Pharma & Healthcare Update: June 24,2022
TCS case may throw spotlight on job termination in IT industry
Quotes : June 23,2022

Events


Webinars

Sustainable Mobility: Opportunities and Challenges
June 09,2022 - June 09,2022

This event is over. For event material please click here


Seminar

Navigating Disputes in India
February 26,2020 - February 26,2020

This event is over. For event material please click here


Round Table

Investing In Net Zero
July 14,2022 - July 14,2022

News Roundup


News Articles

Impact of Supreme Court’s new covidvaccination ruling on India’s employers
May 13,2022

Quotes

TCS case may throw spotlight on job termination in IT industry
June 23,2022

Newsletters


Pharma & Healthcare Update

Mid-year Regulatory Update 2022: Pharmaceuticals in India
June 24,2022

Regulatory Hotline

SEBI’s concerns on Algorithmic Trading by Retail Investors
June 22,2022

Technology Law Analysis

Cyber Security Due Diligence: Should investment committee and board members consider the target’s cyber security readiness before jumping in?
June 20,2022

  • Disclaimer
  • Content
  • Feedback
  • Walkthrough
  • Subscribe
Nishith Desai Associates@2016 All rights reserved.